(Adebrelimab)Biosimilar Reference Antibody-GS40011

货号：GS40011

Adebrelimab is a fully human IgG4 monoclonal antibody targeting the programmed cell death ligand 1 (PD-L1). It functions as an immune checkpoint inhibitor by specifically binding to PD-L1, thereby blocking its interaction with the PD-1 and B7.1 (CD80) receptors on immune cells. This blockade releases the "brakes" on the immune system, particularly on T cells, restoring their ability to recognize and attack tumor cells. Developed by Jiangsu Hengrui Medicine, it is approved in China and is in global clinical trials for various cancers, most notably in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), where it has demonstrated significant survival benefits.